129 lines
42 KiB
Text
129 lines
42 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK23464">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK23464/?report=reader">
|
|
<meta name="ncbi_pagename" content="2-(2-Nitroimidazol-1H-yl)-(3-[18F]fluoropropyl)acetamide - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>2-(2-Nitroimidazol-1H-yl)-(3-[18F]fluoropropyl)acetamide - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/EF5/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/F18-DCFPyL/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="2-(2-Nitroimidazol-1H-yl)-(3-[18F]fluoropropyl)acetamide">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2005/11/17">
|
|
<meta name="citation_author" content="The MICAD Research Team">
|
|
<meta name="citation_pmid" content="20641663">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK23464/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="2-(2-Nitroimidazol-1H-yl)-(3-[18F]fluoropropyl)acetamide">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="The MICAD Research Team">
|
|
<meta name="DC.Date" content="2005/11/17">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK23464/">
|
|
<meta name="description" content="Hypoxia in malignant tumors is thought to be a major factor limiting the efficacy of chemotherapy and radiotherapy, and its accurate diagnosis is considered a very important and urgent problem to address. This has led to the search and development of hypoxia-targeted, non-invasive markers of tumor hypoxia. Among those markers, [18F]-labeled nitroimidazoles, used in conjunction with positron emission tomography (PET), offer an alternative that is less invasive and less prone to sampling error than the Eppendorf (oxygen) electrode method (1, 2).">
|
|
<meta name="og:title" content="2-(2-Nitroimidazol-1H-yl)-(3-[18F]fluoropropyl)acetamide">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Hypoxia in malignant tumors is thought to be a major factor limiting the efficacy of chemotherapy and radiotherapy, and its accurate diagnosis is considered a very important and urgent problem to address. This has led to the search and development of hypoxia-targeted, non-invasive markers of tumor hypoxia. Among those markers, [18F]-labeled nitroimidazoles, used in conjunction with positron emission tomography (PET), offer an alternative that is less invasive and less prone to sampling error than the Eppendorf (oxygen) electrode method (1, 2).">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK23464/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/EF-mono/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK23464/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E03497D64A651000000000032002E.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK23464/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/EF5/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">2-(2-Nitroimidazol-1H-yl)-(3-[18F]fluoropropyl)acetamide</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/F18-DCFPyL/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK23464/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK23464/&text=2-(2-Nitroimidazol-1H-yl)-(3-%5B18F%5Dfluoropropyl)acetamide"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK23464/?report=classic">Switch to classic view</a><a href="/books/NBK23464/pdf/Bookshelf_NBK23464.pdf">PDF (135K)</a><a href="/books/NBK23464/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK23464%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E03497D64A651000000000032002E.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK23464_"><span class="title" itemprop="name">2-(2-Nitroimidazol-1<i>H</i>-yl)-(3-[<sup>18</sup>F]fluoropropyl)acetamide</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">[<sup>18</sup>F]EF1</div><p class="contribs">The MICAD Research Team.</p><p class="fm-aai"><a href="#_NBK23464_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figEFmonoT1"><a href="/books/NBK23464/table/EF-mono.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figEFmonoT1" rid-ob="figobEFmonoT1"><img class="small-thumb" src="/books/NBK23464/table/EF-mono.T1/?report=thumb" src-large="/books/NBK23464/table/EF-mono.T1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="EF-mono.T1"><a href="/books/NBK23464/table/EF-mono.T1/?report=objectonly" target="object" rid-ob="figobEFmonoT1">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Rodents
|
|
</p></div></div><div id="EF-mono.Background"><h2 id="_EF-mono_Background_">Background</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=18F%5BAll%20Fields%5D%20AND%20EF1%5BAll%20Fields%5D%20AND%20synthesis%5BAll%20Fields%5D" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Hypoxia in malignant tumors is thought to be a major factor limiting the efficacy of chemotherapy and radiotherapy, and its accurate diagnosis is considered a very important and urgent problem to address. This has led to the search and development of hypoxia-targeted, non-invasive markers of tumor hypoxia. Among those markers, [<sup>18</sup>F]-labeled nitroimidazoles, used in conjunction with positron emission tomography (PET), offer an alternative that is less invasive and less prone to sampling error than the Eppendorf (oxygen) electrode method (<a class="bibr" href="#EF-mono.EXTYLES.1" rid="EF-mono.EXTYLES.1">1</a>, <a class="bibr" href="#EF-mono.EXTYLES.2" rid="EF-mono.EXTYLES.2"> 2</a>).</p><p>Fluoromisonidazole (<a href="/books/n/micad/FMISO/?report=reader">[<sup>18</sup>F]FMISO</a>) is the most widely used nitroimidazole derivate used with PET. Novel 2-nitroimidazoles, such as <a href="/books/n/micad/FETA/?report=reader">[<sup>18</sup>F]FETA</a> (<a class="bibr" href="#EF-mono.EXTYLES.3" rid="EF-mono.EXTYLES.3">3</a>), <a href="/books/n/micad/FETNIM/?report=reader">[<sup>18</sup>F]FETNIM</a> (<a class="bibr" href="#EF-mono.EXTYLES.4" rid="EF-mono.EXTYLES.4">4</a>), <a href="/books/n/micad/BrFPN/?report=reader">4-Br[<sup>18</sup>F]FPN</a> (<a class="bibr" href="#EF-mono.EXTYLES.5" rid="EF-mono.EXTYLES.5">5</a>), [<sup>18</sup>F]EF1, and <a href="/books/n/micad/EF5/?report=reader">[<sup>18</sup>F]EF5</a> (<a class="bibr" href="#EF-mono.EXTYLES.6" rid="EF-mono.EXTYLES.6">6</a>), are currently being investigated as potential markers of tumor hypoxia.</p><p>[<sup>18</sup>F]EF1 is a molecule comparable to [<sup>18</sup>F]FETA, with the exception that [<sup>18</sup>F]EF1 carries an additional carbon on the side chain. [<sup>18</sup>F]EF1 is also a 3-monofluorinated analog of the pentafluorinated molecule EF5 (2-(2-nitro-1<i>H</i>-imidazol-1-yl)-<i>N</i>-(2,2,3,3,3-[<sup>18</sup>F]pentafluoropropyl)acetamide), which is used for the measurement of hypoxia in immunohistochemistry (<a class="bibr" href="#EF-mono.EXTYLES.7" rid="EF-mono.EXTYLES.7">7</a>) and flow cytometry (<a class="bibr" href="#EF-mono.EXTYLES.8" rid="EF-mono.EXTYLES.8">8</a>).</p><p>The oxygen-dependent metabolism of nitroimidazoles is an intracellular process consisting of a series of one-electron reductions. The nitro-radical anion produced in the first reduction step is very reactive toward oxygen, leaving no substrate for the second step of the reduction process. In contrast, a low-oxygen environment induces further reductive reactions that ultimately lead to the formation of either reactive products that can covalently bind to cell components or to charged species that diffuse slowly out of the tissues (<a class="bibr" href="#EF-mono.EXTYLES.1" rid="EF-mono.EXTYLES.1">1</a>). The reactive products observed during this multi-step process include nitroso (2e-), hydroxylamine (4e-), and amine (6e-) derivatives. When the fragmentation of the imidazole ring occurs, reactive portions of the molecule, such as glyoxal, bind to macromolecular components of cells in tissues and tumors (<a class="bibr" href="#EF-mono.EXTYLES.2" rid="EF-mono.EXTYLES.2">2</a>).</p></div><div id="EF-mono.Synthesis"><h2 id="_EF-mono_Synthesis_">Synthesis</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=18F%5BAll%20Fields%5D%20AND%20EF1%5BAll%20Fields%5D%20AND%20synthesis%5BAll%20Fields%5D" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Two modes of synthesis for [<sup>18</sup>F]EF1 were reported in 1999 by Kachur et al. (<a class="bibr" href="#EF-mono.EXTYLES.9" rid="EF-mono.EXTYLES.9">9</a>).</p><p>In the first mode, EF1 is synthesized from EBr1 by a nucleophilic substitution of bromine by fluorine using potassium Kryptofix 222 fluoride in dimethyl sulfoxide (DMSO). EBr1 is prepared from 2-(2-nitroimidazol-1<i>H</i>-yl)-acetic acid and 3-bromopropylamine hydrobromide using the mixed anhydride reaction with isobutyl chloroformate (<a class="bibr" href="#EF-mono.EXTYLES.10" rid="EF-mono.EXTYLES.10">10</a>). After dissolution in acetonitrile (MeCN) and storage over molecular sieves, the mixture is cooled to 0ºC under argon and stirred with an addition of isobutylchloroformate. A solution of 3-bromopropylamine hydrobromide (219 mg, 1 mmol) and 140 μl of NEt<sub>3</sub> (1 mmol) in 5 ml of MeCN is then added. After stirring, cooling to 0°C, and centrifugation, the resulting precipitate of NEt<sub>3</sub>H<sup>+</sup>Cl− is extracted and dried at room temperature. The final product, EBr1, is then recrystallized from hexane/EtOAc (10:1 ratio) and dried over molecular sieves. EBr1 is obtained with a yield of approximately 70%.</p><p>In the second mode, EF1 is prepared by following the protocol used for EBr1 described above, except that an equivalent quantity of 3-fluoro- instead of 3-bromopropylamine is used. In this case, the C–F bond in EF1 (which is not hydrolyzed) reacts with an excess of triethylamine (unlike the C–Br bond in EBr1). In this second method, the reaction conditions and separation procedure are different: a 2-fold excess of triethylamine is used in the reaction, and the dried reaction mixture, after centrifugation, is dissolved in dry EtOAc. After evaporation and dissolution of the residue in CHCl<sub>3</sub>, EF1 is extracted by H<sub>2</sub>O, and the aqueous layers are then combined and lyophilized. The yield is approximately 15% pure EF1.</p><p>The preparation of the radioactive carrier is performed by using [<sup>18</sup>F]fluoride, obtained by the <sup>18</sup>O(p,n) <sup>18</sup>F reaction using <sup>18</sup>O-enriched water. Details for this preparation are reported by Kachur et al. (<a class="bibr" href="#EF-mono.EXTYLES.9" rid="EF-mono.EXTYLES.9">9</a>).</p></div><div id="EF-mono.In_Vitro_Studies_Tes"><h2 id="_EF-mono_In_Vitro_Studies_Tes_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=18F%5BAll%20Fields%5D%20AND%20EF1%5BAll%20Fields%5D%20AND%20%28%22in%20vitro%22%5BMeSH%20Terms%5D%20OR%20in%20vitro%5BText%20Word%5D%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="EF-mono.Animal_Studies"><h2 id="_EF-mono_Animal_Studies_">Animal Studies</h2><div id="EF-mono.Rodents"><h3>Rodents</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%2818F%29EF1%20AND%20%22rodentia%22%5BMeSH%20Terms%5D" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Evans et al. (<a class="bibr" href="#EF-mono.EXTYLES.11" rid="EF-mono.EXTYLES.11">11</a>) showed the ability of [<sup>18</sup>F]EF1 to differentiate hypoxic <i>versus</i> aerobic tumors in rodents, using the hypoxic Morris 7777 (Q7) hepatoma tumor type and the oxic 9LF glioma tumor model. The experimental procedure involved injecting intravenously approximately 1.9 MBq (0.05 mCi) of [<sup>18</sup>F]EF1 (1% of the animal’s weight), 3 m<span class="small-caps">m</span> of the carrier EF1,and 7 m<span class="small-caps">m</span> EF3 (2-(2-nitro-1<i>H</i>-imidazol-1-yl)-<i>N</i>-(2,2,3,3,3-[<sup>18</sup>F]trifluoropropyl)acetamide). The specific activity of [<sup>18</sup>F]EF1 for injection was 5.6 × 10<sup>4</sup> MBq/mol (1.51 × 10<sup>3</sup> mCi/mol).</p><p>The use of an excess of the carrier drug EF1 and EF3 made it possible to make an independent assessment of the drug biodistribution by more conventional means (e.g., high-performance liquid chromatography (HPLC)), as well as making an immunohistochemical detection of intracellular EF1/EF3 adducts in the tumors using EF3-specific antibodies. Biodistribution of [<sup>18</sup>F]EF1 was also performed in non-tumor-bearing mice, as a reference. After positron emission tomography (PET) studies, the tissues for all animals were removed and analyzed by γ-counting at 1, 5, 90, and 120 min after injection.</p><p>Results showed that for both rat tumor types, low retention of [<sup>18</sup>F]EF1 was obtained in muscle, heart, spleen and brain, whereas significantly higher levels were found in tumor and bone (tibia). γ-counts of excised organs and tissues were measured at 90 min after injection, and their uptake was expressed as a percentage of injected activity per gram of sample (% ID/g). The following results (% ID/g) were found for muscle, heart, spleen, brain, tumor, and bone (tibia), respectively (all values are x 10−<sup>3</sup>): for Q7 tumors, 2.5, 1.5, 3.0, 1.5, 6.5, and 13; for 9LF tumors, 1.5, 1.0, 1.8, 0.6, 2.5, and 12 (<a class="bibr" href="#EF-mono.EXTYLES.11" rid="EF-mono.EXTYLES.11">11</a>).</p><p>Studies using normal mice showed a rapid decrease of activity in all organs except bone (tibia), likely reflecting a bone contamination by [<sup>18</sup>F]F<sup>-</sup> and a very substantial increase of urine activity by 90 min after injection (0.6 fraction ID/g). For Q7 tumors, the tumor-to-muscle ratio (T/M) initially decreased (from approximately 2.0 at 10 min after injection to 1.7 at 50 min) and then increased (to approximately 2.4) to reach a plateau 125 min after injection. In contrast, the T/M ratio for 9L tumors never exceeded 1.0, and a steady decrease was observed over time (<a class="bibr" href="#EF-mono.EXTYLES.11" rid="EF-mono.EXTYLES.11">11</a>).</p></div><div id="EF-mono.Other_NonPrimate_Mam"><h3>Other Non-Primate Mammals</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%2818F%29EF1%20AND%20%28dog%20OR%20pig%20OR%20sheep%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="EF-mono.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%2818F%29EF1%20AND%20%28primate%20NOT%20human%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div></div><div id="EF-mono.Human_Studies"><h2 id="_EF-mono_Human_Studies_">Human Studies</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%2818F%29EF1%20AND%20human" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="EF-mono.references"><h2 id="_EF-mono_references_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.1">Nunn A , Linder K , Strauss HW . Nitroimidazoles and imaging hypoxia. <span><span class="ref-journal">Eur J Nucl Med. </span>1995;<span class="ref-vol">22</span>(3):265–280.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7789400" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7789400</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.2">Hodgkiss RJ . Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. <span><span class="ref-journal">Anticancer Drug Des. </span>1998;<span class="ref-vol">13</span>(6):687–702.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9755725" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9755725</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.3">Rasey JS , Hofstrand PD , Chin LK , Tewson TJ . Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. <span><span class="ref-journal">J Nucl Med. </span>1999;<span class="ref-vol">40</span>(6):1072–1079.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10452326" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10452326</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.4">Yang DJ , Wallace S , Cherif A , Li C , Gretzer MB , Kim EE , Podoloff DA . Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. <span><span class="ref-journal">Radiology. </span>1995;<span class="ref-vol">194</span>(3):795–800.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7862981" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7862981</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.5">Yamamoto F , Aoki M , Furusawa Y , Ando K , Kuwabara Y , Masuda K , Sasaki S , Maeda M . Synthesis and evaluation of 4-bromo-1-(3-[18F]fluoropropyl)-2-nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent. <span><span class="ref-journal">Biol Pharm Bull. </span>2002;<span class="ref-vol">25</span>(5):616–621.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12033502" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12033502</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.6">Dolbier WR , Li AR , Koch CJ , Shiue CY , Kachur AV . [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. <span><span class="ref-journal">Appl Radiat Isot. </span>2001;<span class="ref-vol">54</span>(1):73–80.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11144255" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11144255</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.7">Evans SM , Joiner B , Jenkins WT , Laughlin KM , Lord EM , Koch CJ . Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5. <span><span class="ref-journal">Br J Cancer. </span>1995;<span class="ref-vol">72</span>(4):875–882.</span> [<a href="/pmc/articles/PMC2034029/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2034029</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7547234" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7547234</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.8">Evans SM , Jenkins WT , Joiner B , Lord EM , Koch CJ . 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. <span><span class="ref-journal">Cancer Res. </span>1996;<span class="ref-vol">56</span>(2):405–411.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8542599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8542599</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.9">Kachur AV , Dolbier WR , Evans SM , Shiue CY , Shiue GG , Skov KA , Baird IR , James BR , Li AR , Roche A , Koch CJ . Synthesis of new hypoxia markers EF1 and [18F]-EF1. <span><span class="ref-journal">Appl Radiat Isot. </span>1999;<span class="ref-vol">51</span>(6):643–650.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10581679" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10581679</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.10">Krejcarek GE , Tucker KL . Covalent attachment of chelating groups to macromolecules. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>1977;<span class="ref-vol">77</span>(2):581–585.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/409400" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 409400</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="EF-mono.EXTYLES.11">Evans SM , Kachur AV , Shiue CY , Hustinx R , Jenkins WT , Shive GG , Karp JS , Alavi A , Lord EM , Dolbier WR , Koch CJ . Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. <span><span class="ref-journal">J Nucl Med. </span>2000;<span class="ref-vol">41</span>(2):327–336.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10688119" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10688119</span></a>]</div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK23464_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">The MICAD Research Team</span></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">November 5, 2005</span>; Last Update: <span itemprop="dateModified">November 17, 2005</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>The MICAD Research Team. 2-(2-Nitroimidazol-1H-yl)-(3-[18F]fluoropropyl)acetamide. 2005 Nov 5 [Updated 2005 Nov 17]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/EF5/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/F18-DCFPyL/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobEFmonoT1"><div id="EF-mono.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK23464/table/EF-mono.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__EF-mono.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2-(2-Nitroimidazol-1<i>H</i>-yl)-<i>N</i>-(3-[<sup>18</sup>F]fluoropropyl)acetamide</td><td rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/7854919" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=7854919" alt="image 7854919 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> [<sup>18</sup>F]EF1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[<sup>18</sup>F]-2-(2-Nitro-1<i>H</i>-imidazol-1-yl)-<i>N</i>-(3-fluoropropyl)acetamide</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Compound</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hypoxic cells </td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intracellular reduction and binding</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PET</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>18</sup>F</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li id="A807" class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li><li id="A808" class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Rodents
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Click on the above structure for additional information in <a href="http://pubchem.ncbi.nlm.nih.gov" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubChem</a>.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|